Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 10Gynecologic 6Dermatologic 5Thoracic 4Breast 4Sarcoma 3Head & Neck 3Genitourinary 3Lymphoid 1Endocrine 1CNS 1

Conditions

Sarcoma 1573Glioblastoma 512Gliosarcoma 485Osteosarcoma 459Brain Neoplasms 344Gastrointestinal Stromal Tumors 326Central Nervous System Neoplasms 296Neoplasms 291Dendritic Cell Sarcoma, Interdigitating 286Astrocytoma 275Lymphoma 260Bone Neoplasms 245Sarcoma, Ewing 238Breast Neoplasms 238Glioma 237Neuroblastoma 230Rhabdomyosarcoma 227Melanoma 225Precursor Cell Lymphoblastic Leukemia-Lymphoma 218Recurrence 216Lymphoma, Non-Hodgkin 216Burkitt Lymphoma 213Oligodendroglioma 203Ovarian Neoplasms 202Lymphoma, Large B-Cell, Diffuse 187Neoplasm Metastasis 186Lymphoma, Follicular 172Leukemia 164Leukemia, Lymphocytic, Chronic, B-Cell 158Hodgkin Disease 158

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Vaccinia × Sarcoma × Clear all
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Vaccinia, Colorectal Neoplasms

NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Transgene

Phase 1/2 Terminated
31 enrolled
BreastDermatologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT01169584 2016-01-21

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

SillaJen, Inc.

Phase 1 Completed
6 enrolled
CNSGenitourinaryLymphoidSarcoma

Lymphoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Vaccinia, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡